Skip to content

Participate in our active studies Subscribe to our Mailing List

AB Science

Masitinib and AB8939 – Two compounds with breakthrough mechanism of action

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

Search:

Home
Company
Science
Pipeline
News and Media
Investors
Masivet®
- About Masivet®
- Medical information and Pharmacovigilance
Careers
Contact

AB Science Corporate Presentation

You are here:

Home
Investor Relations
AB Science Corporate Presentation

AB Science Corporate Presentation

Post navigation

PreviousPrevious post:Positive top-line Phase 3 results for masitinib in severe asthma NextNext post:Clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities

Related Posts

Governance
May 9, 2018

General Meeting preparatory documents
May 6, 2018

Other information
May 5, 2018

Frequently Asked Questions
May 1, 2018

Search

Search:

Recent Posts

AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
AB Science announces the successful completion of a 2.8 million euros private placement
Summary of the virtual conference held on October 16, 2025

AB SCIENCE
HEADQUARTER

3, Avenue George V – 75008 PARIS – FRANCE
Tel. : +33 (0)1 47 20 00 14
Fax. : +33 (0)1 47 20 24 11

GENERAL INQUIRIES

contact@ab-science.com

PRODUCT INQUIRIES

masivet@ab-science.com

JOB INQUIRIES

careers@ab-science.com

CLINICAL INQUIRIES

clinical@ab-science.com

MEDIA / FINANCIAL INQUIRIES

investors@ab-science.com

PHARMACOVIGILANCE

pharmacovigilance@ab-science.com
Fax : +33 1 47 20 10 82

© AB Science – All right reserved